Response to the Letter to the Editor: "Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease"

被引：0

作者：

Casanova, Maria Jose

Chaparro, Maria

Gisbert, Javier P.

机构：

[1] Univ Autonoma Madrid, Gastroenterol Unit, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP, Madrid, Spain

[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

来源：

INFLAMMATORY BOWEL DISEASES | 2020年 / 26卷 / 02期

关键词：

D O I：

10.1093/ibd/izz287

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Almost 50% of patients who switch to a second anti-tumor necrosis factor (anti-TNF) drug after failure of a first anti-TNF will achieve remission. However, a high proportion of these patients will experience loss of response. Before deciding to switch to a second anti-TNF, the reason for switching and the probability of loss of response should be taken into account.

引用

页码：E6 / E6

页数：1

共 50 条

[1] Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease
Bauer, Christina M.
Younis, Adam
Herfarth, Hans
Barnes, Edward L.
INFLAMMATORY BOWEL DISEASES, 2020, 26 (02) : E5 - E5
[2] Satisfactory Switch to Infliximab after Adalimumab Loss of Response in a Teenager with Severe Crohn's Disease
Nita, Andreia Florina
Becheanu, Gabriel
Pacurar, Daniela
EUROPEAN JOURNAL OF PEDIATRICS, 2019, 178 (11) : 1668 - 1668
[3] Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab
Peeters, H.
Louis, E.
Baert, F.
Dewit, O.
Coche, J. C.
Ferrante, M.
Lambrecht, G.
Colard, A.
Van Gossum, A.
Bossuyt, P.
Moreels, T.
Vander Cruyssen, B.
Gils, A.
De Vos, M.
ACTA GASTRO-ENTEROLOGICA BELGICA, 2018, 81 (01) : 15 - 21
[4] Efficacy of switching to infliximab in Crohn's disease patients with loss of response to adalimumab
Peeters, H.
Louis, E.
Baert, F.
Dewit, O.
Coche, J. -C.
Ferrante, M.
Lambrecht, G.
Colard, A.
Van Gossum, A.
Bossuyt, P.
Moreels, T.
De Vos, M.
JOURNAL OF CROHNS & COLITIS, 2014, 8 : S274 - S274
[5] EVALUATION OF PREDICTORS OF DURABLE CLINICAL RESPONSE TO INFLIXIMAB AFTER SECONDARY LOSS OF RESPONSE TO ADALIMUMAB AMONG PATIENTS WITH CROHN'S DISEASE
Younis, Adam
Barnes, Edward L.
Herfarth, Hans H.
GASTROENTEROLOGY, 2019, 156 (06) : S1139 - S1140
[6] An open label study of adalimumab in Crohn's disease patients with a loss of response to infliximab
Anwar, Malik
O'Sullivan, Maria
Ryan, Barbara
Breslin, Niall
O'Connor, Humphrey
O'Morain, Colm
GASTROENTEROLOGY, 2006, 130 (04) : A662 - A662
[7] Mechanisms of Loss of Response to Adalimumab in Crohn's Disease
Wolf, Douglas C.
Hauenstein, Scott
Lockton, Steven
Singh, Sharat
GASTROENTEROLOGY, 2013, 144 (05) : S775 - S775
[8] What Is the Rate of Loss of Response to Infliximab Therapy in Crohn's Disease? Response
Gisbert, Javier P.
Panes, Julian
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (09): : 2354 - 2355
[9] Clinical Response to Infliximab after Secondary Failure with Adalimumab or Certolizumab Pegol in Crohn's Disease
Trivella, Juan
Yarur, Andres
Moroney, James
Deshpande, Amar
Abreu, Maria
Sussman, Daniel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S560 - S561
[10] Predictors of Loss of Response to Infliximab in Pediatric Crohn's Disease
Selvakumar, Praveen Kumar Conjeevaram
Szpunar, Susan
Lyons, Hernando
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S594 - S594

← 1 2 3 4 5 →